Single-, double-, and triple-blinding apply progressively to patients, investigators, and outcome assessors. Device trials often achieve only assessor-blinding due to the visible nature of devices/procedures. When patients and operators cannot be blinded, trials often use blinded independent assessors, core labs and clinical events committees to reduce bias. Sponsors document the blinding approach in the clinical investigation plan and check blinding success where possible. Unblinding procedures for emergencies must be defined so safety is not compromised.

Why it matters

Independent core labs and blinded adjudication committees are standard mitigations for device trials where full blinding is impossible.

Common pitfalls

•Failure to document the rationale for the chosen blinding level can lead to regulatory scrutiny.
•Inadequate blinding procedures can compromise the scientific validity of clinical trial results, leading to questions from regulatory authorities.
•Assuming that device trials cannot be blinded at all, rather than seeking opportunities for partial blinding, is a common pitfall.
•Not accounting for potential unblinding events and having a plan to address them can undermine study integrity.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.